Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted
In addition to chasing companies in the category with already-marketed drugs - which also include Roche, AstraZeneca and Merck KGaA/Pfizer - Novartis’PDR001 and INCSHR-1210 from Incyte/Jiangsu Hengrui are
Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms.
to Incyte and Novartis’rival JAK inhibitor Jakafi (ruxolitinib), which grew 35% to $831m in the first nine months of 2017.
Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....